RECEPTORAI Showcases Advances in AI-Driven Drug Discovery and Structural Modeling

RECEPTORAI is using recent communications to spotlight progress across its AI-driven drug discovery platform, with a particular focus on challenging targets and complex modalities. The company emphasized work on a DNA repair and recombination protein where traditional approaches struggled to identify viable small-molecule binders.

Instead of simply expanding screening volume, RECEPTORAI reported narrowing a virtual library of up to 10^16 compounds using DNA-like pharmacophores and its StratAI decision engine. This workflow, combined with ArtiDock docking and higher-fidelity physics-based methods, delivered 18 structurally diverse hits below 10 μM potency, including a lead with an IC50 of 1.6 μM.

Management framed this case as evidence that its platform can tackle broad, shallow and highly charged protein surfaces, where conventional pocket-focused chemistry is less effective. For potential partners, such capabilities may position the firm as a specialist in rescuing or de-risking difficult discovery programs.

RECEPTORAI also highlighted concerns about systematic biases in AlphaFold 3 for protein design and interaction modeling. Citing a Georgia Tech preprint, the company noted that AlphaFold 3 structures often remain largely unchanged under disruptive mutations, with high confidence scores potentially driven by template reliance.

According to RECEPTORAI, this behavior can yield implausible protein–protein interfaces and large disordered regions in co-folding predictions. The firm points to its own workflows as a corrective layer, aiming to mitigate model bias and improve reliability of structural inputs for downstream discovery.

In parallel, the company is deepening its focus on peptide drug discovery by incorporating new Journal of Medicinal Chemistry findings on membrane permeability into its platform. Its proprietary physics-based workflow generates conformational ensembles across aqueous and membrane environments to feed an AI permeability predictor.

By targeting permeability, a core bottleneck for macrocyclic and cyclic peptides, RECEPTORAI aims to reduce late-stage failures and improve candidate quality for partners. The combined emphasis on complex DNA repair targets, AlphaFold-aware modeling and peptide permeability suggests a deliberate R&D strategy to differentiate its technology stack.

If these capabilities translate into consistent results across programs, the company could strengthen its positioning as a partner of choice in AI-enabled drug discovery. Overall, the week’s developments underscore RECEPTORAI’s push to address some of the most technically challenging aspects of computational chemistry and structural biology.